or Try an Advanced Search...

    Technical Analysis for MIRM - Mirum Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    B 34.16 -0.09% -0.03
    MIRM closed down 0.09 percent on Monday, July 1, 2024, on approximately normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Up
    Historical MIRM trend table...
    Date Alert Name Type % Chg
    Shooting Star Candlestick Bearish 0.00%
    Wide Bands Range Expansion 0.00%
    Overbought Stochastic Strength 0.00%
    Pocket Pivot Bullish Swing Setup -0.09%
    Volume Surge Other -0.09%
    Stochastic Reached Overbought Strength -0.09%
    Wide Bands Range Expansion -0.09%
    Overbought Stochastic Strength -0.09%
    NR7 Range Contraction 3.17%
    NR7-2 Range Contraction 3.17%
    Older End-of-Day Signals for MIRM ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown about 8 hours ago
    Up 3% about 10 hours ago
    Rose Above Previous Day's High about 10 hours ago
    Up 2% about 10 hours ago
    Up 1% about 10 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    MIRM Chart by TradingView
    Basic chart:

    Profile

    Mirum Pharmaceuticals, Inc., a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). It is also developing Volixibat, an investigational oral inhibitor of ASBT, a protein that is primarily responsible for recycling bile acids from the intestine to the liver. The company was incorporated in 2018 and is based in Foster City, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Acid Recycling Liver Disease Hepatology Progressive Digestive Diseases Liver Bile Acid Primary Biliary Cholangitis Cholestasis Intrahepatic Cholestasis

    Is MIRM a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 28 MercadoLibre, A Few Other Growth Stocks, Among New Faces In IBD 50
    Jun 28 Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX
    Jun 25 Biotech Stock Explodes On Drug Trial News As Sales Keep Doubling
    Jun 18 Mirum (MIRM) Soars on Interim Data From Liver Disease Studies
    Jun 18 Mirum Pharmaceuticals (MIRM) Soars 27.3%: Is Further Upside Left in the Stock?
    Jun 17 Mirum stock climbs after positive interim data from liver disease drug
    Jun 17 Mirum Pharmaceuticals Advances after Reporting Positive Trial Results for Prospective Cholangitis Treatment
    Jun 17 Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies
    Jun 16 Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024
    Jun 7 Why Is Mirum Pharmaceuticals (MIRM) Down 3.4% Since Last Earnings Report?
    See more MIRM news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 35.56
    52 Week Low 23.14
    Average Volume 716,208
    200-Day Moving Average 28.23
    50-Day Moving Average 26.71
    20-Day Moving Average 29.33
    10-Day Moving Average 32.78
    Average True Range 1.76
    RSI (14) 66.10
    ADX 38.6
    +DI 40.58
    -DI 9.11
    Chandelier Exit (Long, 3 ATRs) 30.17
    Chandelier Exit (Short, 3 ATRs) 29.10
    Upper Bollinger Bands 36.62
    Lower Bollinger Band 22.04
    Percent B (%b) 0.83
    BandWidth 49.72
    MACD Line 2.30
    MACD Signal Line 1.79
    MACD Histogram 0.5094
    Fundamentals Value
    Market Cap 1.59 Billion
    Num Shares 46.6 Million
    EPS -4.27
    Price-to-Earnings (P/E) Ratio -8.00
    Price-to-Sales 9.01
    Price-to-Book 4.85
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 36.22
    Resistance 3 (R3) 36.42 35.93 35.88
    Resistance 2 (R2) 35.93 35.40 35.83 35.76
    Resistance 1 (R1) 35.05 35.08 34.80 34.85 35.65
    Pivot Point 34.56 34.56 34.43 34.46 34.56
    Support 1 (S1) 33.67 34.03 33.43 33.47 32.67
    Support 2 (S2) 33.18 33.71 33.08 32.56
    Support 3 (S3) 32.30 33.18 32.44
    Support 4 (S4) 32.10